期刊文献+

HPLC法测定孟鲁司特钠咀嚼片的含量及有关物质 被引量:2

Content Determination and Related Substances of Montelukast Sodium Chewable Tablets by HPLC
原文传递
导出
摘要 目的:建立孟鲁司特钠咀嚼片含量测定及有关物质检查的方法。方法:采用高效液相色谱法。色谱柱为VenusilXBPC18(L),流动相为乙腈-0.025mol/L乙酸铵溶液(含0.02%十二烷基硫酸钠,pH值8.0)(68:32,V/V),流速为1.0ml/min,柱温为25℃,检测波长为270nm。结果:在选定的色谱条件下,主成分能与各杂质之间良好分离。孟鲁司特钠检测质量浓度线性范围为0.05~0.3mg/m(lr=0.9999),平均回收率为98.9%,RSD=0.4%(n=9),定量限为3.7ng。结论:建立的测定方法灵敏度高、专属性强,可用于孟鲁司特钠咀嚼片的质量控制。 OBJECTIVE: To establish a method for the content determination of Montelukast sodium chewable tablets and the related substances. METHODS: HPLC method was adopted. The determination was performed on a Venusil XBP C18 (L) column with mobile phase consisted of acetonitrile-0.025 mol/L ammonium acetate solution containing 0.02% sodium laurylsulfate (pH ad- justed to 8.0, 68 : 32, V/V) at the flow rate of 1.0 ml/min. The column temperature was set at 25 %. The detection wavelength was set at 270 nm. RESULTS: Related substances were completely separated from the main constituent. The linear rang of montelukast sodium was 0.05-0.3 mg/ml (r=0.999 9) with an average recovery of 98.9% (RSD=0.4%, n=9). The limit of quantitation for montelukast sodium was 3.7 ng. CONCLUSIONS: The method is simple and specific, which can be used for the quality control of Montelukast sodium chewable tablets.
出处 《中国药房》 CAS CSCD 2013年第5期456-458,共3页 China Pharmacy
关键词 孟鲁司特钠咀嚼片 含量测定 有关物质 高效液相色谱法 Montelukast sodium chewable tablets Content determination Related substances HPLC
  • 相关文献

参考文献8

二级参考文献30

  • 1曹玲,陈育智.孟鲁司特治疗儿童哮喘的有效性及安全性观察[J].中华微生物学和免疫学杂志,2001,21(S2):65-67. 被引量:22
  • 2李伟,宁奇.扎鲁司特的合成[J].中国医药工业杂志,2004,35(8):451-452. 被引量:3
  • 3谢沐风.简介日本“药品品质再评价”工程(溶出度研究系列一)[J].中国药品标准,2005,6(6):42-46. 被引量:133
  • 4张相林,李凯鹏,丁庆明,刘晓,王辉.孟鲁司特钠药动学及其国产片剂/咀嚼片剂人体相对生物利用度研究[J].中国新药杂志,2006,15(9):728-731. 被引量:19
  • 5Knorr B, Larson P, Nguyen HH, et al. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol, 1999,39:786-793.
  • 6Reiss TF, Chervinsky P, Dockhorn R J, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial[J]. Arch Intern Med, 1998, 158 (11) : 1 213.
  • 7Lee MY, Lai YS, Yang KD, et al. Effects of montelukast on symptoms and eNO in children with mild to moderate asthma[J]. Pediatr lnt, 2005,47 (6) : 622.
  • 8国家药典委员会编冲华人民共和国药典(二部)[S].2005年版.北京:化学工业出版社,2005:附录ⅣA、XC.
  • 9Thibert R, Mach H, Clas SD, et al. Characterization of the self-association properties of a leukotriene D4 recep- tor antagonist, MK-0476[J]. Int J Pharm, 1996, 134 (1-2):59.
  • 10Green SA,Malice MP,Tanaka W,et al.Increase in urinary leukotriene LTE4 levels in acute asthma:correlation with airflow limitation[J].Thorax,2004,59:100-104.

共引文献106

同被引文献7

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部